77 reports

  • Cystic Fibrosis Products
  • Cystic Fibrosis Products

It' s estimated that ## in every ##, ## babies born in the UK has cystic fibrosis.

  • Cystic Fibrosis
  • World
  • Market Size
  • AbbVie Inc.
  • Editas Medicine, Inc.
  • 6 Cystic Fibrosis Market, By Regions
  • ASIA-PACIFIC CYSTIC FIBROSIS MARKET, BY COUNTRY, 2015 (%)

Cystic fibrosis is one of the rare chronic disease.

  • Cystic Fibrosis
  • AbbVie Inc.
  • Allergan plc
  • Pharmaxis Ltd
  • Vertex Pharmaceuticals Incorporated
  • 6 Cystic Fibrosis Market, By Regions
  • GLOBAL CYSTIC FIBROSIS MARKET, BY REGION, 2015 (%)

Cystic fibrosis is one of the rare chronic disease.

  • Cystic Fibrosis
  • AbbVie Inc.
  • Allergan plc
  • Pharmaxis Ltd
  • Vertex Pharmaceuticals Incorporated
  • 2.6.4 CYSTIC FIBROSIS
  • 2.5.4 CYSTIC FIBROSIS

CYSTIC FIBROSIS.

  • Cystic Fibrosis
  • Market Size
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Biologics, Inc.

##.

  • Cystic Fibrosis
  • Pathology
  • World
  • Market Size

Global Cystic Fibrosis Therapeutics Market Outlook 2022 ##.

  • Cystic Fibrosis
  • Therapy
  • World
  • Company Financials
  • Market Size
  • Cystic Fibrosis
  • Clinical Manifestations and Complications of Cystic Fibrosis

One of the major non-profit organizations working in this field is the Cystic Fibrosis Foundation.

  • Cystic Fibrosis
  • Therapy
  • World
  • AbbVie Inc.
  • Vertex Pharmaceuticals Incorporated
  • EMILY DIMANGO, MD
  • STUART JOSEPH ELBORN, MD

Journal of Cystic Fibrosis; ##(##): ##-##.

  • Cystic Fibrosis
  • Canada
  • France
  • Italy
  • Forecast

Cystic Fibrosis Forecast and Market Analysis to 2025 CONTENTS ## FORECAST: CYSTIC FIBROSIS (Published on ## September 2018) ## OVERVIEW ## MARKET DYNAMICS ## FORECAST AND FUTURE TRENDS ## MARKET DEFINITION AND METHODOLOGY ## PRIMARY RESEARCH METHODOLOGY ## BIBLIOGRAPHY ## P

  • Cystic Fibrosis
  • Pathology
  • European Union
  • United States

Global Cystic Fibrosis Therapeutics Market 2016-2026 ##.

  • Cystic Fibrosis
  • Pathology
  • United States
  • World
  • Forecast
  • 2 Cystic Fibrosis: Executive Summary
  • CYSTIC FIBROSIS: KEY METRICS IN THE SEVEN MAJOR PHARMACEUTICAL MARKETS

JOURNAL OF CYSTIC FIBROSIS; ##(##): ##-##.

  • Cystic Fibrosis
  • Forest Laboratories, Inc.
  • Novartis AG
  • Pharmaxis Ltd
  • Vertex Pharmaceuticals Incorporated

Cystic Fibrosis (CF) Therapeutics Market Analysis By Drug Class (Pancreatic Enzyme Supplements, Mucolytics, Bronchodilators, CFTR Modulators), By Route of Administration, By Region, And Segment Forecasts, 2014 - 2025 Table of Contents Chapter ##.

  • Cystic Fibrosis
  • Therapy
  • United States
  • Forecast

Cystic Fibrosis Phase ## Clinical Trials, 2016 ##.

  • Cystic Fibrosis
  • Pathology
  • United States
  • Market Shares
  • Market Size

Global Cystic Fibrosis Epidemiology and Patient Flow Analysis - 2016 ##.

  • Cystic Fibrosis
  • Pathology
  • United States
  • World
  • Forecast

Cystic Fibrosis Phase ## Clinical Trials, 2016 ##.

  • Cystic Fibrosis
  • France
  • Germany
  • Market Shares
  • Market Size

Cystic Fibrosis Phase ## Clinical Trials, 2016 ##.

  • Cystic Fibrosis
  • Pathology
  • Japan
  • Market Shares
  • Market Size

Cystic Fibrosis Phase ## Clinical Trials, 2016 ##.

  • Cystic Fibrosis
  • Pathology
  • United States
  • Market Shares
  • Market Size

Cystic Fibrosis Phase ## Clinical Trials, 2016 ##.

  • Cystic Fibrosis
  • Pathology
  • United Kingdom
  • Market Shares
  • Market Size

Cystic Fibrosis Phase ## Clinical Trials, 2016 ##.

  • Cystic Fibrosis
  • Pathology
  • Italy
  • Market Shares
  • Market Size

Cystic Fibrosis Phase ## Clinical Trials, 2016 ##.

  • Cystic Fibrosis
  • Pathology
  • Germany
  • Market Shares
  • Market Size

Cystic Fibrosis Phase ## Clinical Trials, 2016 ##.

  • Cystic Fibrosis
  • Pathology
  • France
  • Market Shares
  • Market Size

Cystic Fibrosis Phase ## Clinical Trials, 2016 ##.

  • Cystic Fibrosis
  • Pathology
  • Spain
  • Market Shares
  • Market Size

Bronchitol

8770 10000 7800

Bronchitol CONTENTS ## OVERVIEW ## Drug Overview ## Product Profiles ## Bronchitol : Cystic fibrosis LIST OF FIGURES ## Figure ##: Bronchitol for cystic fibrosis – SWOT analysis ## Figure ##: Datamonitor Healthcare’s drug assessment summary of Bronchitol for

  • Cystic Fibrosis
  • Germany
  • United Kingdom
  • United States
  • Demand

Kalydeco

8770 10000 7800

Kalydeco CONTENTS ## OVERVIEW ## Drug Overview ## Product Profiles ## Kalydeco : Cystic fibrosis LIST OF FIGURES ## Figure ##: Kalydeco for cystic fibrosis – SWOT analysis ## Figure ##: Datamonitor Healthcare’s drug assessment summary of Kalydeco for

  • Cystic Fibrosis
  • Pathology
  • European Union
  • United States
  • Market Description

Orkambi

8770 10000 7800

Orkambi CONTENTS ## OVERVIEW ## Drug Overview ## Product Profiles ## Orkambi : Cystic fibrosis LIST OF FIGURES ## Figure ##: Orkambi for cystic fibrosis – SWOT analysis ## Figure ##: Datamonitor Healthcare’s drug assessment summary of Orkambi for cystic fibrosis ##

  • Cystic Fibrosis
  • Pathology
  • European Union
  • United States
  • Market Description

Pulmozyme

8770 10000 7800

Pulmozyme CONTENTS ## OVERVIEW ## Drug Overview ## Product Profiles ## Pulmozyme : Cystic fibrosis LIST OF FIGURES ## Figure ##: Pulmozyme for cystic fibrosis – SWOT analysis ## Figure ##: Datamonitor Healthcare’s drug assessment summary of Pulmozyme for

  • Cystic Fibrosis
  • Respiratory Treatment
  • Therapy
  • European Union
  • United States

Cayston

8770 10000 7800

It inhibits cell wall synthesis in aerobic Gram-negative bacteria, including Pseudomonas aeruginosa, one of the most common pathogens found in patients with cystic fibrosis.

  • Cystic Fibrosis
  • Respiratory Treatment
  • Therapy
  • European Union
  • United States

Symdeko

8770 10000 7800

The tezacaftor/ ivacaftor combination has been evaluated in a large Phase III program enrolling cystic fibrosis patients with a wide range of genotypes, including at least one copy of the F##del mutation.

  • Cystic Fibrosis
  • Pathology
  • European Union
  • United States

Vertex triple combinations CONTENTS ## OVERVIEW ## Drug Overview ## Product Profiles ## Vertex triple combination program : Cystic fibrosis LIST OF FIGURES ## Figure ##: Vertex triple combination program for cystic fibrosis – SWOT analysis ## Figure ##: Datamonitor Healthc

  • Cystic Fibrosis
  • Pathology
  • European Union
  • United States

Tobi/Tobi Podhaler

8770 10000 7800

Tobi/ Tobi Podhaler CONTENTS ## OVERVIEW ## Drug Overview ## Product Profiles ## Tobi/ Tobi Podhaler : Cystic fibrosis LIST OF FIGURES ## Figure ##: Tobi/ Tobi Podhaler for cystic fibrosis – SWOT analysis ## Figure ##: Datamonitor Healthcare’s drug assessment s

  • Cystic Fibrosis
  • Pathology
  • European Union
  • United States